MRMDOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
MARIMED INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-3.39%)
Close on Oct 19, 2026
- Market cap
- $22.78M
- P/E (TTM)
- –
- Dividend yield
- –
MARIMED INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Online Portal Operations [Member] | – | – | – | – | – | – | – | – | $289 | $618 | – | – |
| Cannabis Operations [Member] | – | – | – | – | – | – | – | – | $6.07M | $3.56M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales - retail | $89.02M | $91.28M | $95.52M | $92.84M | $82.13M | $28.98M | $1.54M | – | – | – | 55.7% | -2.5% |
| Product sales - wholesale | $69.58M | $62.90M | $48.79M | $32.87M | $26.12M | $10.42M | – | – | – | – | 43.5% | +10.6% |
| Other revenue | $1.22M | $3.54M | $4.29M | $8.31M | $13.22M | $1.18K | $48.59K | $113.29K | $228 | – | 0.8% | -65.4% |
| Real estate rentals | – | – | – | – | $6.55M | $6.78M | $6.84M | $6.44M | $2.52M | – | – | – |
| Management fees | – | – | $711.00K | $848.00K | $3.08M | $1.48M | $2.80M | $1.58M | $1.19M | – | – | – |
| Supply procurement | – | – | $1.53M | $3.35M | $2.11M | $1.55M | $3.56M | $3.02M | $1.94M | – | – | – |
| Licensing fees | – | – | $261.00K | $582.00K | $1.48M | $1.68M | $1.79M | $700.17K | $269.26K | – | – | – |
| Consulting [Member] | – | – | – | – | – | – | – | $50.00K | $150.60K | – | – | – |
| Product Sales to Related Party [Member] | – | – | – | – | – | – | $29.03M | – | – | – | – | – |
| Product Sales From Related Party [Member] | – | – | – | – | – | – | $29.03M | – | – | – | – | – |
| Total product revenue | – | – | $144.31M | $125.70M | $108.25M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Marimed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.